Latest From Mallinckrodt PLC
Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.
Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
Four distributors and Walgreens also remain defendants; court to consider Teva's motion to dismiss if the trial results in a judgement against its subsidiaries. Seven-week trial could include 215 witnesses and 21,000 exhibits.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Respiratory, Pulmonary
- Mallinckrodt LLC
- Mallinckrodt Inc.
- Mallinckrodt Group, Inc.
- Mallinckrodt Pharmaceuticals
- Western Europe
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
Mark Trudeau, Pres. & CEO
George Kegler, EVP and CFO, Interim
Steven Romano, MD, EVP, CSO
Matthew Harbaugh, President, Specialty Generics
Hugh O'Neill, EVP and Chief Commercial Officer
Dagmar Rosa-Bjorkeson, Chief Strategy and Corp Dev Officer
Frank Scholz, PhD, EVO and Chief Operations/Digital Innovation
- Contact Info
Phone: 17 8463 6700
3 Lotus Park
Staines-Upon-Thames, MO TW18 3AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.